Vaxcyte (Vaxcyte) Debt-to-Equity : 0.01 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte Debt-to-Equity?

Vaxcyte's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $7.20 Mil. Vaxcyte's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $20.22 Mil. Vaxcyte's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $1,983.98 Mil. Vaxcyte's debt to equity for the quarter that ended in Mar. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Vaxcyte's Debt-to-Equity or its related term are showing as below:

PCVX' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.01 Med: 0.01 Max: 0.06
Current: 0.01

During the past 6 years, the highest Debt-to-Equity Ratio of Vaxcyte was 0.06. The lowest was -0.01. And the median was 0.01.

PCVX's Debt-to-Equity is ranked better than
99.91% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs PCVX: 0.01

Vaxcyte Debt-to-Equity Historical Data

The historical data trend for Vaxcyte's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcyte Debt-to-Equity Chart

Vaxcyte Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.06

0.02

Vaxcyte Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															0.02	0.01	0.01	0.02	0.01

Competitive Comparison of Vaxcyte's Debt-to-Equity

For the Biotechnology subindustry, Vaxcyte's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vaxcyte's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vaxcyte's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Vaxcyte's Debt-to-Equity falls into.

Vaxcyte Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Vaxcyte's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.113	+	22.111)	/	1240.468
	=	0.02

Vaxcyte's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(7.202	+	20.218)	/	1983.983
	=	0.01

Vaxcyte (NAS:PCVX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Vaxcyte Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Vaxcyte's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxcyte (Vaxcyte) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (NAS:PCVX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

5VA:Germany

Address

825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070

Website

https://www.vaxcyte.com

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-XP, VAX-A1, and VAX-PG.

Executives

Andrew Guggenhime	officer: CFO, CBO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Grant Pickering	director, officer: President & CEO	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Mikhail Eydelman	officer: SVP, Gen Counsel & Corp Sec	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Jim Wassil	officer: Chief Operating Officer	C/O VAXCYTE, INC., 353 HATCH DRIVE, FOSTER CITY CA 94404
Heath Lukatch	director	326 BOLLAY DRIVE, GOLETA CA 93117
Elvia Cowan	officer: See Remarks Section	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, SUITE 300, SAN CARLOS CA 94070
Jeff Fairman	officer: VP, Research	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Paul Sauer	officer: SVP Process Dev, Manufacturing	C/O VAXCYTE, INC., 825 INDUSTRIAL DRIVE, STE. 300, SAN CARLOS CA 94404
Michael E. Kamarck	director	C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406
Carlos V Paya	director	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Harpreet S. Dhaliwal	officer: SVP Cml Mfg & Supply Chain	C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
Anne S Drapeau	director	C/O IRON MOUNTAIN INCORPORATED, ONE FEDERAL STREET, BOSTON MA 02110
Teri Loxam	director	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
Jane Wright Mitchell	officer: General Counsel	C/0 ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Robert Lorne Hopfner	director	C/O BAY CITY CAPITAL, LLC, 750 BATTERY STREET, SUITE 400, SAN FRANCISCO CA 94111